The first-in-human Phase 1 trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and early signs of anti-tumor activity for FX-111 just started recruiting. We already talked about the rationale behind it in this post. FX-111 is a selective degrader of ARon, the transcriptionally active, hormone-bound form of the androgen receptor. That distinction matters because […]
A study published in Nature Communications, “Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy,” looked at how muscle health affects men with advanced prostate cancer during androgen deprivation therapy. The researchers followed 60 patients over six months and assessed body composition, strength, endurance, quality of life, and skeletal […]
KAIST has reported a new cancer-fighting nanoparticle platform that combines two powerful ideas into one system: helping the immune system notice cancer cells and delivering gene therapy directly into those cells. The basic concept is simple. Instead of only trying to poison or block a tumor from the outside, the nanoparticle makes the cancer cell […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! We never stop scouting for new weapons to fight this battle. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 3 […]
Research presented during ASCO GU 2026, showed that germline DDR variants are common enough in metastatic prostate cancer to matter clinically, but their impact is highly gene-specific. In this 3,005-patient cohort, about 9% carried a germline DDR variant, and the study was especially important because it assessed both small variants and structural variants across 31 […]
Researchers at USC have found that prostate cancer cells may rely on a 3D network of DNA “switches”, called enhancers, to keep cancer genes turned on. Enhancers are not genes themselves; they are stretches of DNA that help control when nearby or distant genes are active and how strongly they are expressed. In this study, […]
VIR-5500 expanded into mHSPC in April 2026, when it announced the first patient had been dosed in the Phase 1 dose-expansion cohorts. VIR-5500 is being studied in late-line mCRPC as monotherapy and, importantly for this expansion, in combination with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC. The move was built on earlier […]
A very interesting Phase 1/2 trial of SL‑28 has started enrolling up to 60 patients with advanced solid tumours at The Southern Oncology Clinical Research Unit (SOCRU). Although the study is open to a broad range of solid cancers, it is particularly noteworthy for prostate cancer because a published case report described a complete response […]
EvoPAR‑Prostate05 is a Phase 3 maintenance trial testing the PARP1‑selective inhibitor saruparib (AZD5305) in men with metastatic hormone‑sensitive prostate cancer (mHSPC). The trial enrolls both HRR‑mutated and non‑HRR‑mutated patients but requires that each participant has confirmed homologous recombination repair mutation status (HRRm – genes such as BRCA1, BRCA2, ATM, PALB2, CDK12, RAD51B/C/D, or BARD1), homologous […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! New weapons on the way! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. I tried a different approach for this podcast, with more […]